Tamtai A, et al. – This study aimed at assessing tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5–FU regimen for locally advanced esophageal and esophagogastric junction cancers. Results indicated comparable efficacy among the carboplatin and paclitaxel (CP) regimen and the platinum/5–fluorouracil (PF) regimen. However, the CP regimen had less toxicity than the PF regimen.